Current Issues & Challenges in the Development of Pharmacopoeial Monographs: European Pharmacopoeia Dr. Susanne Keitel European Directorate for the Quality of Medicines & HealthCare (EDQM) Beijing, 30 March 2010
Apr 01, 2015
Current Issues & Challenges in the Development of
Pharmacopoeial Monographs: European Pharmacopoeia
Dr. Susanne KeitelEuropean Directorate for the Quality of Medicines &
HealthCare (EDQM) Beijing, 30 March 2010
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved22
The Council of EuropeThe Council of Europe
– Founded in 1949– Development of
European common and democratic principles
– 47 member countries– Headquarters in
Strasbourg
Core values : Protection of human rights (European Convention on Human Rights &Fundamental Freedoms), pluralist democracy & the rule of law
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved44
The European UnionThe European Union
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved55
EDQM - Short HistoryEDQM - Short History1964:
– Convention on the Elaboration of a European Pharmacopoeia signed by 8 Member States
1992:– 1st co-operation contract with the EU Commission on the
Biological Standardisation Programme
1994:– European Community signs the Convention– CEP – Implementation of the “Certification of Suitability scheme”– Official Medicines Control Laboratory (OMCL) – Creation of the
Network
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved66
Short HistoryShort History
Change of name: the Secretariat of the European Pharmacopoeia becomes the European Department (and later “Directorate”) for the Quality of Medicines
(and later “& HealthCare”)…
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved77
Progressive Transfer of ActivitiesProgressive Transfer of Activities
2007 – Blood Transfusion and Organ Transplantation
2008 – Pharmaceuticals and Pharmaceutical Care (general pharmaceutical activities)
2009 – Cosmetics and Food Packaging
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved88
Ph.Eur.+ Eur. ObserversPh.Eur.+ Eur. Observers
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved99
In the WorldIn the World
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved1010
ContentContent
1.Is There a Need for A Pharmacopoeia? – Scope
2.Challenges of Globalisation – What Can Pharmacopoeias Contribute?
3.Prospective Harmonisation – a Way to Speed-up the Process?
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved1111
The role of Pharmacopoeias is to Guarantee the Quality of MedicinesThe role of Pharmacopoeias is to Guarantee the Quality of Medicines
• Harmonised specifications for substances of different origins (worldwide trade)
• Transparent monographs (impurity profile)
• Specifications and valid analytical working methods
• Common Reference Substances
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved1212
Why a Monograph ?Why a Monograph ?
• A public standard, an independent evaluation
• One single quality for everybody• Protection of public health via a standard
which represents one known quality• Simplify the compilation of dossiers for
industry and as a result of this the evaluation of marketing authorisation
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved1313
What Type of Monograph ?What Type of Monograph ?
• All active ingredientes and excipients of general interest
• Priority: therapeutic interest, number of patients treated, number of countries where the product is approved, mandatory quality
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved1414
Fields CoveredFields Covered• Active substances (organic, inorganic)• Excipients• Substances of biological and biotechnological origin
(insulin, somatropin…)• Vegetable drugs and preparations, essential and fatty
oils• Radiopharmaceuticals• Vaccines, sera (human, veterinary), blood derivatives• Homoeopathic preparations• ….
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved1515
The UsersThe Users
• Pharmaceutical industry• Pharmaceutical industry suppliers• Regulatory authorities (medicines
agencies)• OMCLs• Others…
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved1616
The European Pharmacopoeia is…The European Pharmacopoeia is…
• A public health instrument• A source of standardisation • A reference and a model for quality in the field of
medicines• Harmonisation of work for 36 European countries
free movement• Competition of industry at « eye level » as they are
bound by the same health standards• Activities based on an international Convention under
the aegis of the Council of Europe
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved1717
ContentContent
1.Is There a Need for A Pharmacopoeia? – Scope
2.Challenges of Globalisation – What Can Pharmacopoeias Contribute?
3.Prospective Harmonisation – a Way to Speed-up the Process?
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved1818
Impact of GlobalisationImpact of Globalisation
• New routes of API synthesis may result in different impurity profiles
• Cost pressure in public health systems may cause frequent changes in suppliers
• A globally acting industry needs harmonised regulatory requirements
• ….
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved1919
General Principles in Elaborating MonographsGeneral Principles in Elaborating Monographs
• SAFETY FIRST!
• Products of proven safety
• Products evaluated and approved by competent
authorities of Member States
• Impurity profiles for existing, approved synthetic
routes
• Robust, validated analytical methods based on
collaborative laboratory testing
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved2020
Directive 2003/63/ECDirective 2003/63/EC
“The monographs of the European Pharmacopoeia shall be applicable to all substances, preparations and pharmaceutical forms appearing in it. In respect of other substances, each Member State may require observance of its own national pharmacopoeia.
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved2121
Directive 2003/63/ECDirective 2003/63/EC
However, where a material in the European Pharmacopoeia … has been prepared by a method liable to leave impurities not controlled in the pharmacopoeia monograph, these impurities and their maximum tolerance limits must be declared and a suitable test procedure must be described.”
Directive 2003/63/EC, 3.2 Content: basic principles Directive 2003/63/EC, 3.2 Content: basic principles and requirementsand requirements
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved2222
Need to Stay Up-Dated Need to Stay Up-Dated
• To serve its purpose, the pharmacopoeia has to stay up-dated with changes in medical practice and technological developments, for example:– The significant growth of biotechnologically
manufactured API– The growing importance of ethnic medicines, e.g.
Traditional Chinese Medicines
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved2323
Need to Stay Up-Dated Need to Stay Up-Dated
• To follow developments in the pharmaceutical industry (change in paradigm introduced by the ICH guidelines Q8, Q9, Q10), while taking into consideration the specific needs of the globally acting industry and small and medium-sized enterprises,
BUT• The protection of public health stays FIRST
PRIORITY!
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved2424
ContentContent
1.Is There a Need for A Pharmacopoeia? – Scope
2.Challenges of Globalisation – What Can Pharmacopoeias Contribute?
3.Prospective Harmonisation – a Way to Speed-up the Process?
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved2525
BackgroundBackground
• International Harmonisation of general monographs and excipients within PDG ongoing, but not on APIs
• Harmonisation of long-existing texts has proven to be – difficult due to different approaches / traditions– slow to take account of stakeholders’ needs in the
different regions who need to adapt
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved2626
Pilot Project Ph.Eur. and USPPilot Project Ph.Eur. and USP
• Common initiative of 2 manufacturers, Ph.Eur. and USP in 2008
• JP has been informed and will observe process and outcome
• Main idea: harmonise prospectively
based on EDQM “P4” procedure for substances still under patent
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved2727
Pilot ProcedurePilot Procedure1. Submission of identical data packages to
EDQM and USP2. After paper review, a common list of
questions is sent to the manufacturer3. EDQM reviews the replies and prepares a
draft to a joint EDQM-P4/USP expert group
4. The draft is verified in parallel in laboratories of EDQM, USP, national authorities (OMCLs) or FDA.
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved2828
Pilot Procedure (2)Pilot Procedure (2)
5. The manufacturer may test in parallel6. All labs reports are exchanged7. The P4 Rapporteur co-ordinates the
discussion on the reports and proposes potential changes of the first draft to the manufacturer
8. A consensus draft is published in Pharmeuropa and Pharmacopoeial Forum
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved2929
Pilot Procedure (3)Pilot Procedure (3)
• Review of public comments coordinated by the P4 Rapporteur in consultation with the joint expert group
• Common version of the final draft must be agreed by all parties
• Sent for adoption by Ph.Eur. Commission and USP committee
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved3030
Pilot Procedure (4)Pilot Procedure (4)
• Any changes during the approval process must be notified to all parties
• Target: identical implementation date
• Evaluation of the pilot process is part of the project
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved3131
Where Do We Stand Today ?Where Do We Stand Today ?
• 4 dossiers from 2 manufacturers received 08-10/2008
• Reviewed by EP and USP
• Joint list of questions sent (10-11/2008)
• Answers from manufacturers received
02/2009-03/2009
• First drafts to be published
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved3232
Potential ProblemsPotential Problems
• Non-harmonised general chapters such as chromatography, heavy metals, water determination etc.
• Establishment of reference substances e.g. availibility of sufficient amounts of
impurity samples
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved3333
OutlookOutlook
• Communication worked well so far
• All parties committed to progress
• The experience might give stimulus to International Harmonisation process
Dr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reservedDr. Susanne Keitel, 30/03/10 ©2010 EDQM, Council of Europe, All rights reserved3434
Quality is never an accident. It is always the result of high
intention, sincere effort, intelligent direction and skilful execution; it represents the wisest choice of
many options.
John Ruskin